Combination BRAF and MEK inhibition provides HRQoL advantage vs BRAF inhibitor monotherapy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • A study of health-related quality of life scores from a phase III study in BRAF Val600 mutation-positive metastatic melanoma found combination dabrafenib + trametinib to provide benefits over vemurafenib monotherapy 
Study Design
  • Pre-specified prospective analysis of HRQoL from a Phase...